*Chance M et al. (2011) PROTEIN BIOMARKERS AND THERAPEUTIC TARGETS FOR RENAL DISORDERS. United States Patent Application 20120329071*Ofotokun I et al. (2011) Immune activation mediated change in alpha-1-Acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol. 51(11):1539-48*Alfadda AA et al. (2012) Orosomucoid serum concentrations and fat depot-specific mRNA and protein expression in humans. Mol Cells. 33(1):35-41*Schlatzer D et al. (2012) Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care. 35(3):549-55. Epub 2012 Jan 11*Lv M et al. (2013) Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One 8(3):e58735*Alfadda AA (2014) Circulating Adipokines in Healthy versus Unhealthy Overweight and Obese Subjects. Int J Endocrinol. 2014:170434. doi: 10.1155/2014/170434. Epub 2014 Jan 16*Martos-Moreno GA et al. (2014) Proteomic analysis allows for early detection of potential markers of metabolic impairment in very young obese children.Int J Pediatr Endocrinol. 2014(1):9. doi: 10.1186* Omran M et al. (2016) A Prospective Pharmacokinetic Study of Docetaxel in Breast Cancer Patients in Relation to CYP3A4 Activity. Clin Pharmacol Biopharm 5:2 (alpha-1-acid Glycoprotein Kit).* Wrzesniak M et al. (2016) The Influence of Tobacco Smoke on Protein and Metal Levels in the Serum of Women during Pregnancy. PLoS One. 11(8):e0161342 * Rodgers P (2017) Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders. Cordis, SchizDX Report Summary, Project ID: 223427, Record Number: 196528